# Stopping GLP-1 Drugs Rapidly Reverses Cardiovascular Benefits Research shows discontinuing Ozempic and similar medications increases heart attack risk by up to 22% - **Source:** [Latest Science News -- ScienceDaily](https://brifing.si/source/0eef8637-6c5b-4e79-8f5b-6c9c6b36cf16) - **Published:** 2026-09-21 - **Original article:** - **On Brifing:** https://brifing.si/s/352479ec-53ad-48fd-8e4e-aa1f291b64f4 ## Cardiovascular protection reversal A study of 333,687 US veterans with type 2 diabetes found that stopping GLP-1 medications like Ozempic eliminates cardiovascular benefits within months. After two years without treatment, patients faced 22% higher risk of heart attack, stroke, and death compared to continuous users. The research published in BMJ Medicine shows these drugs' protective effects disappear faster than they accumulate, with benefits taking years to build but vanishing in months. ## Treatment interruption consequences Even temporary gaps in GLP-1 therapy weaken cardiovascular protection. A six-month interruption reduced benefits by 4-8%, while one year off treatment increased risk by 14%. Patients who restarted medication only partially regained protection, showing discontinuation leaves lasting metabolic damage. The study tracked treatment status every six months over three years, revealing how quickly benefits fade when therapy stops. ## Comparative medication analysis The study compared GLP-1 drugs with sulfonylureas, another diabetes medication class. Continuous GLP-1 users had 18% lower cardiovascular risk than sulfonylurea patients, preventing about 4 major events per 100 people over three years. Those who stopped GLP-1s before 18 months showed no significant risk reduction compared to sulfonylurea users, highlighting the importance of sustained treatment. ## Real-world adherence challenges 26% of study participants stopped GLP-1 drugs completely, while 23% had treatment gaps exceeding six months. Senior author Dr. Ziyad Al-Aly notes many quit due to cost, side effects or shortages. When patients stop, they experience metabolic reversal including increased inflammation, blood pressure and cholesterol - changes not as visible as weight regain but equally dangerous for heart health. ## Metabolic whiplash effect Discontinuing GLP-1 medications causes what researchers call 'metabolic whiplash' - a sudden deterioration of cardiovascular markers. This phenomenon appears particularly damaging to heart health, with restarting therapy only partially restoring protection. The study found each additional year off treatment compounded risk increases, suggesting cumulative damage from treatment interruptions. ## Clinical practice implications Researchers emphasize GLP-1 adherence should be treated as a primary clinical outcome, not an afterthought. They recommend health systems implement support structures for long-term use, including side effect management, patient education about chronic treatment needs, and addressing cost barriers. The findings suggest these medications require indefinite use to maintain cardiovascular protection. ## Study methodology details Conducted by Washington University School of Medicine, the research analyzed VA health records of veterans with type 2 diabetes from 2014-2017. Using rigorous statistical methods, researchers controlled for variables like age, comorbidities and medication history. The large sample size and long follow-up period provide robust evidence about treatment interruption effects rarely captured in clinical trials. ## Chronic disease management shift These findings challenge assumptions about temporary GLP-1 use for weight loss or diabetes management. The data demonstrate these medications work more like chronic disease treatments where stopping therapy carries significant health risks. This has implications for prescribing practices, insurance coverage decisions, and patient counseling about long-term treatment expectations. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/09/260920222414.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._